Search papers, labs, and topics across Lattice.
This paper introduces conDitar-dev, a novel conditional diffusion-based framework for structure-based drug design that generates ligands with both strong binding affinities and favorable ADMET properties. By leveraging a multi-scale pocket representation learning module and a generation-time optimization method, conDitar-dev outperforms existing state-of-the-art methods, achieving an average binding score of -8.85 kcal/mol and improving ADMET property performance by up to 73%. Experimental validation of molecules generated for PD-L1 and CSF1R shows promising biological activity, indicating the framework's practical applicability in drug discovery.
Achieving an average binding score of -8.85 kcal/mol, conDitar-dev not only excels in binding affinity but also optimizes for critical drug developability properties, setting a new standard in computational drug design.
Drug discovery and development is time-consuming and resource-intensive, motivating computational approaches such as diffusion models for de novo drug design. Many such models follow the structure-based drug design (SBDD) paradigm, generating molecules to fit a target binding pocket. However, existing diffusion-based SBDD methods typically couple pocket and ligand representation learning, model interactions only at the atom level, and prioritize binding affinity over other developability properties. Here, we introduce conDitar-dev, a conditional diffusion-based SBDD framework for generating ligands with strong binding affinities and favorable ADMET properties. It consists of three modules: msPRL, a pretrained multi-scale pocket representation learning module; conDitar, a pocket-conditioned diffusion model guided by msPRL representations; and paOPT, a generation-time method for optimizing ligand developability. On a newly curated benchmark of human disease targets, conDitar outperforms state-of-the-art SBDD baselines, achieving an average binding score of -8.85 kcal/mol. Across five ADMET properties, conDitar-dev improves performance by up to 73% over conDitar. To further validate the abilities of conDitar-dev to generate developable molecules, we have applied it to two validated druggable targets: programmed death-ligand 1 (PD-L1) and colony-stimulating factor 1 receptor (CSF1R) proteins. Top-ranked generatively designed molecules and their analogs have been experimentally synthesized and biologically tested. Two molecules generated directly by conDitar-dev for PD-L1 exhibited SPR-derived $K_D$ values of 3.49 and 3.75 $渭$M, respectively. Hit expansion based on conDitar-dev-designed molecules identified selective CSF1R inhibitors with IC$_{50}$ values as low as 200 nM, while also uncovering opportunities for drug repositioning.
